Aytu BioPharma Inc (AYTU) Q2 2026 Earnings Call Highlights: Navigating Challenges and ... [Yahoo! Finance]
Aytu BioPharma, Inc. (AYTU)
NASDAQ:AMEX Investor Relations:
aytubio.com/investors/stock-information
Company Research
Source: Yahoo! Finance
ADHD Portfolio Net Revenue: $13.2 million, compared to $13.8 million in the prior year period. Pediatric Portfolio Net Revenue: $1.7 million, up from $715,000 in the previous quarter. Gross Margin: 63.5%, down from 66.5% last year. Operating Expenses: $11.1 million, compared to $10.2 million in the prior year period. Net Loss: $10.6 million, or $1.05 per share, compared to net income of $0.8 million, or $0.13 per share, in the prior year period. Adjusted EBITDA: Negative $0.8 million, compared to a positive $1.3 million in the prior year period. Cash and Cash Equivalents: $30 million as of December 31, 2025. EXXUA Launch Investment: Reduced to under $8 million from the original $10 million budget. Warning! GuruFocus has detected 9 Warning Signs with AYTU. Is AYTU fairly valued? Test your thesis with our free DCF calculator. Release Date: February 03, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript Aytu B
Show less
Read more
Impact Snapshot
Event Time:
AYTU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AYTU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AYTU alerts
High impacting Aytu BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
AYTU
News
- Aytu BioPharma, Inc. (AYTU) Q2 2026 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Aytu BioPharma (NASDAQ:AYTU) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- Earnings To Watch: Aytu BioPharma Inc (AYTU) Reports Q2 2026 Result [Yahoo! Finance]Yahoo! Finance
- Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026 [Yahoo! Finance]Yahoo! Finance
AYTU
Analyst Actions
- 12/10/25 - Ascendiant Capital
AYTU
Sec Filings
- 2/3/26 - Form 10-Q
- 2/3/26 - Form 8-K
- 1/20/26 - Form 8-K
- AYTU's page on the SEC website